Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death  by Parra, Valentina et al.
Biochimica et Biophysica Acta 1832 (2013) 1334–1344
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isCalcium and mitochondrial metabolism in ceramide-induced
cardiomyocyte deathValentina Parra a,b,1, Francisco Moraga a,1, Jovan Kuzmicic a, Camila López-Crisosto a,
Rodrigo Troncoso a, Natalia Torrealba a, Alfredo Criollo b, Jessica Díaz-Elizondo a,
Beverly A. Rothermel b, Andrew F.G. Quest a,⁎, Sergio Lavandero a,b,⁎⁎
a Centro de Estudios Moleculares de la Célula, Facultad de Ciencias Químicas y Farmacéuticas & Facultad Medicina, Universidad de Chile, Santiago, Chile
b Department of Internal Medicine (Cardiology Division) and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USAAbbreviations: CCCP, carbonyl cyanide m-chloroph
D-erythro-sphingosine-N-acetate; CsA, cyclosporin A;
dyhidro-D-erythro-sphingosine-N-acetate; ER, endopl
dehydrogenase; MP, methyl pyruvate; TMRM, tetram
PI, propidium iodide; ψmt, mitochondrial membrane po
factor alpha
⁎ Correspondence to: A.F.G Quest, Facultad de Me
Independencia 1027, Santiago 8389100, Chile.
⁎⁎ Correspondence to: S. Lavandero, Facultad de Cienc
Universidad de Chile. Olivos 1007, Santiago 8380492, C
E-mail addresses: aquest@med.uchile.cl (A.F.G. Ques
(S. Lavandero).
1 These authors contributed equally to this work.
0925-4439/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbadis.2013.04.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 5 November 2012
Received in revised form 4 April 2013
Accepted 8 April 2013
Available online 16 April 2013
Keywords:
Ceramide
Metabolism
Mitochondrial dynamics
Ca2+
Cell death
CardiomyocyteCeramides are important intermediates in the biosynthesis anddegradationof sphingolipids that regulate numerous
cellular processes, including cell cycle progression, cell growth, differentiation and death. In cardiomyocytes,
ceramides induce apoptosis by decreasing mitochondrial membrane potential and promoting cytochrome-c
release. Ca2+ overload is a common feature of all types of cell death. The aim of this study was to determine the
effect of ceramides on cytoplasmic Ca2+ levels, mitochondrial function and cardiomyocyte death. Our data show
that C2-ceramide induces apoptosis and necrosis in cultured cardiomyocytes by a mechanism involving increased
Ca2+ inﬂux, mitochondrial network fragmentation and loss of the mitochondrial Ca2+ buffer capacity. These
biochemical events increase cytosolic Ca2+ levels and trigger cardiomyocyte death via the activation of calpains.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Thudichum (1884) referred to sphingolipids (from the Greek
Σφιγξ: sphinx) as a peculiar group of lipids because of their enigmatic
nature [1]. Ceramides represent the structural backbone common to
all sphingolipids [2]. Moreover, they regulate several key cellular
processes, including cell cycle, cell growth and differentiation, as well
as cell death. Intracellular de novo synthesis of ceramides occurs in
response to cytokines, environmental stress and chemotherapeutic
agents [2]. Ceramides have also been shown to trigger different forms
of cell death, depending on cell context. In this respect, it should be
noted that they stimulate necrosis in lymphoid cells by increasing ROS
formation and promoting ATP depletion [3].enylhydrazone; C2-ceramide,
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l rights reserved.Sphingolipid alterations occur in obesity and metabolic diseases
where biological processes such as insulin sensitivity, lipid metabolism,
inﬂammation, and immune responses are deregulated [4]. Particularly,
ceramide accumulation has been implicated in the pathogenesis ofmul-
tiple diseases including diabetes, cardiomyopathies and atherosclerosis
[5]. More speciﬁcally, in the cardiovascular system, ceramides regulate
cardiac contractility, vasomotor responses and endothelial function [6]
and they also mediate cardiomyocyte apoptosis triggered by ischemia/
reperfusion [7] or by TNF-α [8]. Moreover, C2-ceramide stimulates
apoptosis in cardiomyocytes by reducing mitochondrial membrane
potential (ψmt) and by activation of caspases 8 and 3 [9]. In addition,
the anti-apoptotic effect of cardiac preconditioning may be due to re-
duced ceramide production during sustained ischemia in the rabbit
heart [10].
Mitochondria play an important role in apoptotic cell death
produced by multiple conditions [11]. C2-ceramide alters ψmt and
promotes cytochrome-c (cyt-c) release and channel formation in the
mitochondrial outermembrane [12,13]. In a previous study, we showed
that C2-ceramide promotes a rapid fragmentation of the mitochondrial
network in a concentration- and time-dependentmanner and, as a conse-
quence, the early activation of apoptosis [14]. Accordingly, C2-ceramide
also stimulates mitochondrial network fragmentation in HeLa cells,
which was linked to ER Ca2+ release and cell death [15].
The contribution of Ca2+ to cell death processes has been extensively
described [16,17]. Ca2+ overload is a common feature of all types of cell
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both early and late stages of the apoptotic process [18]. Ca2+ release
from ER and capacitative Ca2+ inﬂux through Ca2+ release-activated
Ca2+ channels have also been implicated in apoptosis [15,19,20]. In ad-
dition, ceramides cause the release of Ca2+ from the ER, increasing
Ca2+ in both the cytosol, and the mitochondrial matrix. Accordingly,
buffering cytoplasmic Ca2+ prevents mitochondrial damage and
protects HeLa cells from apoptosis [15].
The aim of the current study was to investigate the molecular
mechanisms involved in ceramide-dependent cardiomyocyte death
and more speciﬁcally the role of cytoplasmic Ca2+ and mitochondria
in this process. Our data show that C2-ceramide induces apoptosis
and necrosis in cultured cardiomyocytes by increasing cytoplasmic
Ca2+ and promoting loss of mitochondrial function.
2. Materials and methods
2.1. Reagents
Cell culture reagents, Hanks medium, Dulbecco's modiﬁed Eagle's
medium (DMEM), M199 medium, pancreatin, gelatin, Triton X-100,
5-bromo-2′-deoxyuridine, gadolinium chloride, propidium iodide (PI),
methyl pyruvate (MP), carbonyl cyanide m-chlorophenylhydrazone
(CCCP), oligomycin, FITC-conjugated anti-IgG mouse antibody and the
chemical inhibitors E64D, leupeptin, Z-VAD-fmk, Z-VDAD-fmk and the
lactic dehydrogenase (LDH) kit were purchased from Sigma-Aldrich
Co (St. Louis, MO). The sphingolipids D-erythro-sphingosine-N-acetate
(C2) and dihydro-D-erythro-sphingosine-N-acetate (DH-C2), cyclospor-
in A (CsA) and HRP-conjugated secondary antibodies anti-IgG rabbit
and mouse were from Calbiochem (La Jolla, CA). Antibodies against
cytochrome-c (cyt-c) and anti-α-spectrin were from BD Pharmingen
(San Diego, CA) and EMD Millipore (Billerica, MA), respectively.
Anti-caspase 3 antibody was purchased in Cell Signaling (Danvers,
MA). Fluo 3-AM and tetramethylrhodamine methyl ester (TMRM) were
from Invitrogen (Carlsbad, CA). Organic and inorganic compounds, salts,
acids and solvents were purchased from Merck (Darmstadt, Germany).
CellTiter-Glo Luminescent Cell Viability Assay was purchased from
Promega (Madison WI).
2.2. Animals
Rats were bred in the Animal Breeding Facility, Faculty of Chemical
and Pharmaceutical Sciences, University of Chile (Santiago, Chile).
Studies were approved by the Institutional Bioethical Committee,
Faculty of Chemical and Pharmaceutical Sciences, University of
Chile, in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals published by the US (NIH Publi-
cation No. 85-23, revised 1996).
2.3. Culture of cardiomyocytes
Cardiomyocytes were prepared from hearts of 1- to 3-d-old
Sprague–Dawley rats as described previously [21]. Cells were
maintained in DMEM/M199 (4:1) medium containing 10% FBS and
serum-starved for 24 h prior stimulation. Cells were plated at a density
of 1–8 × 103/mm2 on gelatin-coated 6-, 12-, 24- and 96-wells or
35-mm Petri dishes. For Ca2+ and immunoﬂuorescence studies, cells
were plated on gelatin-coated 25- and 18-mm glass coverslips in
35 mm or 12-well Petri dishes, respectively.
2.4. Cell viability and apoptosis assays
The integrity of the plasma membrane was assessed by determining
the ability of cells to exclude propidium iodide (PI). The level of PI incor-
porationwas quantiﬁed in a FACScan ﬂow cytometer (Becton-Dickinson,
San Jose, CA). Cell size was evaluated by forward-angle light scattering(FSC). PI-negative cells of normal size were considered viable [22,23].
Sub-G1 population was determined in cardiomyocytes permeabilized
with methanol and labeled with propidium iodide (PI). Then the cells
were analyzed using ﬂow cytometry [22,24].
2.5. Mitochondrial membrane potential assay
Mitochondrial membrane potential (ψmt) was measured as de-
scribed previously [24]. Brieﬂy, cells were loaded with 200 nM
TMRM (used in nonquenching mode) for 30 min at 37 °C. After-
wards, cells were trypsinized and ﬂuorescence was assessed by
ﬂow cytometry (λexcitation = 543 nm; λemission = 560 nm) using a
FACScan system (Becton-Dickinson, San Jose, CA,). CCCP 50 μM for
30 min was used as positive control of mitochondrial depolarization.
2.6. Intracellular and mitochondrial Ca2+ measurements
Intracellular and mitochondrial Ca2+ signals were determined as
described previously [25–27]. Images were obtained from cultured
cardiomyocytes preloaded with Fluo3-AM or RhodFF using an
inverted confocal microscope (Carl Zeiss LSM-5, Pascal 5 Axiovert
200microscope). Coverslipsweremounted in a 1-mL capacity chamber
and placed in themicroscope for ﬂuorescencemeasurements after exci-
tation with a laser line of 488-nm for Fluo3-AM or 543-nm for RhodFF.
The ﬂuorescent images were collected every 0.4–2.0 s for fast signals
and analyzed frame by frame with Image J software (NIH, Bethesda,
MD).
2.7. Immunoﬂuorescence studies for cytochrome-c release
Cyt-c release was evaluated by immunoﬂuorescence as described
previously [14]. Cardiomyocytes grown on coverslips were ﬁxed
with PBS containing 4% paraformaldehyde for 10 min, permeabilized
with 0.3% Triton X-100 for 10 min, and blocked for 1 h with 5% BSA in
PBS. Cells were then incubated with anti-cyt-c antibody at 1:400 and
revealed with anti-mouse IgG-Alexa 488. Coverslips were mounted in
DakoCytomation ﬂuorescence mounting medium (DakoCytomation,
Carpinteria, CA) and visualized by confocal microscope (Carl Zeiss
Axiovert 135, LSM Microsystems).
2.8. Intracellular ATP levels
Cellular ATP content was measured using the luciferin/luciferase
based ATP detection kit CellTiter-Glo Luminiscent Cell Viability
Assay (Promega) following the manufacturer's instructions. Brieﬂy,
cardiomyocytes were cultured in 96-well Petri dishes and washed 3
timeswith PBS before incubationwith the reagent. Sample luminescence
was quantiﬁed in a TopCount NXT microplate luminescence counter
(Perkin-Elmer, Waltham, MA). Data was normalized as fold over control.
2.9. Western blot analysis
Equal amounts of protein from cells were separated by SDS-PAGE
(10% polyacrylamide gels) and electrotransfered to nitrocellulose.
Membranes were blocked with 5% milk in Tris-buffered saline, pH 7.6,
containing 0.1% (v/v) Tween 20 (TBST). Membranes were incubated
with primary antibodies at 4 °C and re-blotted with horseradish
peroxidase-linked secondary antibody [1:5000 in 1%(w/v) milk in
TBST]. The bandswere detected using ECL reagent followedby exposure
to Kodak ﬁlm and then quantiﬁed by scanning densitometry. Proteins
were normalized to β-tubulin levels.
2.10. LDH release assay
Necrosis was measured by quantifying LDH activity in culture
medium. LDH activity was determined by measuring the decrease
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in the presence of lactate (2.5 mg/mL). The fraction of LDH released
was determined by comparing LDH activity in the culture medium
relative to total LDH activity.
2.11. Cardiomyocyte transfection
Small interfering RNAs (siRNA) for calpains I and II and negative
control (Mission, Sigma-Aldrich Corp., St Louis, MO) were used
following the manufacturer's instructions. Cells were grown and
after 48 h, transfected with siRNAs at a concentration of 25 nM with
Lipofectamine™ RNAiMAX (Invitrogen, Carlsbad, CA). After 6 h incuba-
tion in Opti-mem ®, the medium was removed and replaced with 10%
FBS in DMEM/M199. Calpain I/II down-regulation was assessed 48 h
post-transfection. The siRNAs used for knockdown experiments were
as follows:
- Negative control, catalog number SIC001;
- Calpain Ia, sense (5′-GUUGUGACCUUUGAUCUAU-3′), antisense
(5′-AUAGAUCAAAGGUCACAAC-3′)
- Calpain Ib, sense (5′-CUGACUAUGUUUGCAUGAA-3′), antisense
(5′-UUCAUGCAAACAUAGUCAG-3′)
- Calpain IIa, sense (5′-GAACGUACGGGAACAUUUA-3′), antisense
(5′-UAAAUGUUCCCGUACGUUC-3′)
- Calpain IIb, sense (5′-GUUUCAAGCUGCCCUGUCA-3′), antisense
(5′-UGACAGGGCAGCUUGAAAC-3′)
Different combinations of two siRNAs against each calpain were
tested, obtaining the best results with the siRNA mixture containing
the speciﬁc siRNAs Ia and IIa, whichwas used for all the subsequent ex-
periments (Supplementary Fig. 1A).
2.12. RNA puriﬁcation and real-time reverse transcription-PCR (RT-PCR)
Total RNA was isolated using TRIzol according to the manufacturer's
protocol (Invitrogen, Carlsbad, CA). Random hexamers were used for
reverse-transcription reactions using superscript II (Invitrogen, Carlsbad,
CA). RT-PCRwas performed using SYBR green (Invitrogen, Carlsbad, CA).
Data for each transcript were normalized to both GAPDH and 18S rRNA
as internal controls using the 2-ΔΔCt method. The primers used are
listed below:
Calpain 1 Rat Forward 5′-TGGAGATCAGTGTCAAGGAGTTAC-3′
Calpain 1 Rat Reverse 5′-GCACTCATGCTGCCAGACTTGTCCAGGTCA-3′
Calpain 2 Rat Forward 5′-GGGCAGACCAACATCCACCTCAGCAAAAAC-3′
Calpain 2 Rat Reverse 5′-ATCTCCGCATCCTCTCCAGCCAGC-3′
2.13. Expression of results and statistical analysis
Data are presented either as means ± SD of a number (n) of inde-
pendent experiments or as examples of representative experiments
performed on at least three separate occasions. Data were analyzed by
analysis of variance and comparisons between groups were performed
using a protected Tukey t-test. A value of p b 0.05 was chosen as the
limit of statistical signiﬁcance.
3. Results
3.1. C2-ceramide induces apoptosis and necrosis in cardiomyocytes
Currently, there are conﬂicting views concerning the role of
ceramides as second messengers in several cardiac pathologies [28].
One possibility to explain the death-promoting functions of ceramides
invokes damage tomitochondria and alterations in calciumhomeostasis.
Whether suchmechanismsmaybe relevant in cardiomyocytes remained
to be determined. Thus, we investigated the types of cell death induced
by C2-ceramide in cultured rat cardiomyocytes and the role of Ca2+and mitochondria in these events. For these experiments, we used a
serum-free culturemodel to enhance sensitivity and detectmore readily
the cell death induced by C2-ceramide than previously described [14]. As
shown in Fig. 1A the treatment of cardiomyocytes with C2-ceramide
20 μM during a 6 h period induces a signiﬁcant increase in the sub G1
population (from 8.0% ± 1.6 to 24.2% ± 2.0), indicative of apoptosis,
which however does not account for the total cell death observed
under these conditions, as evaluated by PI incorporation (from
7.8% ± 0.9 to 41.4% ± 5.1). Importantly, this effect was not observed
when the cells were treated with the inactive analog, dihydro-
C2-ceramide, discarding a detergent effect of these short-chain lipids.
The same treatment with C2-ceramide also stimulated LDH release, as
determined by measuring the activity of this enzyme in the culture
medium (from 10.0% ± 0.5 to 33.3% ± 6.8), as well as a decrease in
the ψmt and the intracellular levels of ATP (−26.8% ± 3.4 and −
30.3% ± 2.3, using CCCP 50 μM or oligomycin 2 μM as negative and
positive controls, respectively) (Fig. 1B–D). Moreover, the treatment
of cardiomyocytes with C2-ceramide also induced substantial release
of cyt-c after 1–3 h of treatment. This effect decreased upon exposure
to C2-ceramide for longer periods of time (Fig. 1E). Collectively, these
results suggest that the treatment of cardiomyocytes with C2-ceramide
induces cell death by a mechanism that involved time-dependent early
apoptosis followed by a delayed necrosis.
3.2. Ca2+ inﬂux triggered by C2-ceramide stimulates cardiomyocyte death
Ceramide-induced cell death has often been associated with incre-
ments in the levels of two intracellular second messengers, Ca2+ and
ROS [29–31]. To study the role of both messengers, two different
approaches were used. ROS were measured by electron spin resonance
(ESR) using the spin trap DMPO, whereas Ca2+ inﬂux was assayed
by confocal microscopy using the ﬂuorescent probe Fluo 3-AM.
C2-ceramide (20 μM) did not change the intracellular levels of
ROS in cultured cardiomyocytes (Fig. 2A). Moreover the presence of
antioxidants, including N-acetyl cysteine (NAC), Trolox (a water-
soluble derivative of vitamin E) and Tiron did not reduce the
C2-ceramide-induced cell death (Fig. 2B). On the other hand, ceramide
increased cytoplasmic Ca2+ levels in a manner that was dependent
on the presence of external Ca2+ (Fig. 3A). To investigate whether
this Ca2+ signal contributes to cell death triggered by ceramide,
cardiomyocytes were pretreated either with the Ca2+ chelating
agent EGTA (2 mM) or with GdCl3 (10 μM), a potent but nonselective
antagonist of nonselective cation currents [32]. Both agents decreased
PI incorporation into the cells after treatment with C2-ceramide and
also prevented decreases in ψmt and intracellular ATP levels
(Fig. 3B–D), whereby Gd3+ was much more effective than EGTA. Ad-
ditionally, both EGTA and Gd3+ delayed cyt-c redistribution, which
under these conditions was nomore longer signiﬁcant at 3 h of treat-
ment (Fig. 3E).
3.3. Calpains but not caspases are involved in cardiomyocyte death
induced by C2-ceramide
To shed light on mechanisms underlying cell death induced by
C2-ceramide, activation of two important downstream effectors and
key cell death mediators was evaluated in cardiomyocytes, namely
the cysteine protease caspases and Ca2+-dependent calpains [33].
The activation of these proteases was evaluated by determining the
cleavage of pro-caspase 3 to active caspase-3 and of α-spectrin, an
important target of activated calpains [34]. As shown in the Supplemen-
tary Fig. 1B–C, under our experimental conditions only α-spectrin
cleavage was detected, suggesting that calpains are activated in our ex-
perimental model. Moreover, the inhibitors of caspases Z-VDAD-fmk
(50 μM) or Z-VAD-fmk (50 μM) did not prevent cell death induced by
C2-ceramide, whereas the calpain inhibitors leupeptin (100 μM) or
E64D (10 μM) did (Fig. 4A–B). Interestingly, leupeptin also attenuated
Fig. 1. C2-ceramide induces apoptosis and necrosis in cultured cardiomyocytes. (A) Cells were treated with C2-ceramide (C2, 20 μM) or the inactive analog dihydroceramide
(DH-C2) at the same concentration. After 6 h, PI incorporation and the subG1 population were quantiﬁed by FACS analysis. Values are shown as the mean ± SD of 3 independent
experiments, ***P b 0.001. (B) Cells were incubated with C2-ceramide or DH-C2 (20 μM for 6 h) and necrosis was determined by the extent of LDH release to the culture medium.
Data represent means ± SD (n = 3). ***P b 0.001 vs. Control (Co). (C–D) Quantiﬁcation of the mitochondrial membrane potential (ψmt) and the intracellular levels of ATP in cells
treatedwith C2-ceramide or DH-C2 (20 μM, 6 h). Values aremeans ± SD of n = 5 and 6 experiments, respectively, *P b 0.05, *P b 0.005 and ***P b 0.001 vs. Co. (E) Cells were incubated
with C2-ceramide (C2, 20 μM)or DH-C2 for the indicated period of time and cytochrome-cwas detected by indirect immunoﬂuorescence analysis. Cytochrome-c redistributionwas quan-
tiﬁed by counting the cells with a diffuse pattern of ﬂuorescence. (n = 7), **P b 0.01, ***P b 0.001 vs. control and ##P b 0.01 vs. C2-ceramide (C2) 3 h.
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However, neither E64D nor leupeptin prevented the decrease in ψmt
in cells exposed to C2-ceramide (Supplementary Fig. 2).
Given that some calpain inhibitors are rather non-speciﬁc [35] and
that calpains I and II (also known as μ-calpain and m-calpain, respec-
tively) are both expressed in the heart requiring high Ca+2 concen-
tration to be activated [36], both calpain isoforms were knockeddown using siRNA technology. Fig. 4C shows that siRNAS against
calpains I and II prevented the cell death induced by C2-ceramide.
These results were similar to those obtained by the use of calpain in-
hibitors. Also, this strategy did not revert the decrease in the ψm and
the intracellular levels of ATP (Fig. 4D–E). Altogether, these results
suggest that mitochondrial dysfunction occurs prior to the onset of
the calpain-dependent cell death induced by ceramides.
Fig. 2. Ceramide does not stimulate ROS generation in cardiomyocytes. (A) Cells were incubated with C2-ceramide (C2, 20 μM) for a 6 h period in the presence of DMPO (200 mM)
for 30 min. Cells were lysed and extracts were analyzed by electron spin resonance (ESR). Spectrometer conditions: microwave frequency 9.83 GHz, microwave power 20 mW,
modulation amplitude 0.2 G, scan rate 1.25 G/s, time constant 0.5 s, and number of scans: 20. Plots are representative of 3 independent experiments (n = 3). (B) Effect of the antioxidant
agents N-acetylcysteine (NAC, 5 mM), Trolox (5 mM) and Tiron (5 mM) on PI incorporation in cardiomyocytes treated with C2 ceramide (C2, 20 μM) for 6 h. (n = 3), ***P b 0.001 vs.
control (Co).
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function
Wehave previously shown that C2-ceramide induced fragmentation
of the mitochondrial network in cultured rat cardiomyocytes. For this
reason, we evaluated here whether mitochondrial ﬁssionwas triggered
under our experimental conditions and whether this process was also
regulated by the Ca+2 inﬂux. Following the treatment for 6 h withC2-ceramide (20 μM) in serum-freemedium, substantial mitochondrial
network fragmentationwasdetected (Fig. 5A–B), as evidenced by an in-
crease in the number of mitochondria per cell and a decrease in mean
mitochondrial volume, both considered as criteria to document mito-
chondrial ﬁssion [14,37,38]. Moreover, this mitochondrial fragmenta-
tion process was prevented by the pre-incubation of cardiomyocytes
with EGTA and Gd+3 (Fig. 5A–B), thereby connecting our previous
results (Fig. 3) with the onset of mitochondrial dysfunction.
Fig. 3. Ca2+ inﬂux induced by C2-ceramide modulates cardiomyocyte death. (A) Changes in internal cytosolic Ca2+ were investigated in individual, ﬂuo3-AM-loaded cells
maintained inmediumwith or without Ca2+. Cells were stimulated with C2-ceramide (C2, 20 μM) or the control (DMSO vehicle) for the time indicated by the arrow. Results are expressed
as relative total ﬂuorescence [ratio of ﬂuorescence difference (F − Fo), to basal value (Fo)] × 100 as a function of time and are representative of 5 independent experiments in which at least
20 cells were analyzed in each case. The effect of the chelating agent EGTA (1 mM) and Gd+3 (10 μM)were studied in cells treated with C2-ceramide (C2, 20 μM) for 6 h on (B) PI incorpo-
ration, n = 3; (C)mitochondrial potential, n = 5; and (D) intracellular levels of ATP, n = 7, *P b 0.05 vs. Control (Co) and #P b 0.05 vs. C2 6 h. (E) Effect of EGTA (1 mM) andGd+3 (10 μM)
pre-incubation on the redistribution of cytochrome-c in cells treated with C2-ceramide (C2, 20 μM), n = 7, **P b 0.01, ***P b 0.001 vs. Control (Co), #P b 0.05 and ###P b 0.001 vs. C2 3 h.
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ptosis is still controversial [39,40], our previous data [14] established
a model whereby loss of ψmt precedes mitochondrial ﬁssion, which isthen followed by the release of cyt-c. These results suggested that
ceramide-inducedmitochondrialﬁssion is required to trigger apoptosis.
Moreover, the pre-incubation of cardiomyocytes with cyclosporine A
Fig. 4. Calpains but not caspases are involved in cardiomyocyte death induced by C2-ceramide. PI incorporation analysis in cells treated with C2-ceramide (C2, 20 μM) for 6 h and
pre-incubated (30 min) with (A) the caspase 2 (Z-VDAD-fmk) and pan-caspase (Z-VAD-fmk) inhibitors (50 μM), n = 3 or (B) the calpain inhibitors leupeptin (Leu, 100 μM) and
E64D (10 μM), n = 5. ***P b 0.001 vs. Control (Co) and #P b 0.05 vs. C2 6 h. Effect of the calpain I and II knockdown (siCalpI/II) in cells treated with C2-ceramide (C2, 20 μM 6 h) on
the (C) PI incorporation, n = 3; (D) mitochondrial potential, n = 3; and (E) intracellular levels of ATP, n = 3. *P b 0.05, **P b 0.01, ***P b 0.001 vs. a negative siRNA Control (siCo)
and ##P b 0.01 vs. siCo C2 6 h.
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in the development of mitochondrial dependent cell death, almost
completely suppressed C2-ceramide-enhanced PI incorporation, as
well as decreased ψmt and intracellular ATP levels (Fig. 5C–E).
Subsequently, we sought to establish a direct relationship between
the increase in cytosolic Ca2+ inﬂux observed in cardiomyocytes treated
with C2-ceramide and decreased mitochondrial Ca2+ buffer capacity,
which was previously described for fragmented mitochondria [41,42].
To that end, we loaded the cells with the mitochondrial Ca2+ dye
Rhod-FF and then added histamine, a classical agent that evokes a
Ins(3,4,5)P3-dependent Ca2+ release from the ER [43]. As shown in
Fig. 5F, histamine-stimulatedmitochondrial Ca2+ uptakewas signiﬁcant-
ly lower in ceramide-pretreated cardiomyocytes than controls. These re-
sults suggest that fragmented mitochondria in C2-ceramide-treated cells
display decreased ER-mitochondria coupling. Moreover, these observa-
tions are indicative of reduced Ca2+ buffering capacity thatmay explain
the increase in the cytosolic Ca2+ and subsequent activation of calpains
as effectors of cell death.
Finally, it is well known that mitochondrial Ca2+ uptake stimulates
mitochondrial metabolism, in terms of mitochondrial respiration
and ATP production because the activities of dehydrogenases in the
Krebs cycle are stimulated by Ca2+ either directly (isocitrate and
α-ketoglutarate dehydrogenases) or indirectly (pyruvate dehydro-
genase) [44]. If C2-ceramide causes mitochondrial fragmentation and
as a consequence affects mitochondrial Ca2+ uptake and metabolism,
we hypothesized that stimulating mitochondrial metabolism should
decrease ceramide-induced cell death, by precluding decreased ψmt
and ATP levels. To test this idea, we sought to bypass the requirement
for mitochondrial Ca2+ by enhancing the availability of TCA cycle inter-
mediates and increasing the production of reducing equivalents. To
this end, cells were pre-incubated with membrane-permeable methyl-
pyruvate (MP) that is oxidized to provide reducing equivalents
(NADH), which then drive oxidative phosphorylation and ATP produc-
tion [45]. Fig. 6A–C shows that MP partially prevented ceramide-induced cardiomyocyte death, as assessed by PI incorporation, the
decrease in the ψmt as well as the decrease in the intracellular levels of
ATP.
4. Discussion
Our data summarized in the graphical abstract strongly suggest
that C2-ceramide induces cardiomyocyte death through a molecular
mechanism involving enhanced Ca2+ inﬂux, increased mitochondrial
fragmentation and a reduction in themitochondrial Ca2+ buffer capacity.
These changes lead to an increase in cytosolic Ca2+ levels, which is
depicted here as responsible for the activation of calpains. Interestingly,
some of these effects were partially overcome by medium supplementa-
tion with membrane-permeable methyl-pyruvate. Our data also show
that C2-ceramide induces both early apoptosis and delayed necrosis.
The former is dependent on Ca+2 inﬂux (Fig. 3E) and thus can be blocked
by preventing either the rise in cytoplasmic Ca2+ or loss ofmitochondrial
function and both approaches protect cardiomyocytes against ceramide-
induced cell death.
4.1. Ceramide-induced cardiomyocyte death
A considerable body of evidence implicates ceramides in apoptotic
cardiomyocyte death [28]. However, several recent reports in other cell
types suggest that cell death with necrotic features may occur due to in-
creased endogenous ceramide levels, as well as in response to treatment
with cell-permeable ceramides [46–50]. In this study,we sought to deﬁne
the molecular mechanisms by which cell-permeable ceramides promote
cardiomyocyte death. Our current study relies heavily on the use of aﬂow
cytometry assay that identiﬁes different cell populations on the basis of
ﬂuorescence intensity due to DNA staining by PI that enters the cell as a
consequence of augmented membrane permeability [3,46]. In order to
evaluate whether cardiomyocyte membrane permeability to PI triggered
by exposure to cell-permeable C2-ceramide correlated with release of
Fig. 5. C2-ceramide induces cardiomyocyte death by modulating mitochondrial function. (A) Mitochondrial fragmentation induced by C2-ceramide (C2, 20 μM) was studied in
cardiomyocytes pre-incubated (30 min) with or without EGTA (1 mM) and Gd+3 (10 μM). Cells were incubated with C2-ceramide for 6 h and then loaded with mitotracker
green. Multi-slice imaging reconstitution was obtained by confocal microscopy to show mitochondrial morphology. The scale bar is 20 μm. (B) The mean mitochondrial volume and
the number of mitochondria per cell were determined. Values shown are mean ± SD, n = 4, ***P b 0.001 vs. Control (Co) and ###P b 0.001 vs. C2 6 h. The effect of the mitochondrial
transition pore inhibitor, cyclosporine (CsA, 250 nM) was studied in cells treated with C2-ceramide (C2, 20 μM) for 6 h on (C) PI incorporation, n = 3; (D) mitochondrial potential,
n = 4 and; (E) intracellular levels of ATP, n = 5. **P b 0.01, ***P b 0.001 vs. Control (Co), #P b 0.05, ##P b 0.01 and ###P b 0.001 vs. C2 6 h. (F) Representative traces of mitochondrial
calcium ([Ca2+]m) obtained from cardiomyocytes loaded with the Rhod-FF calcium probe, either untreated (Control) or treated with C2-ceramide (C2, 20 μM) for 6 h prior to histamine
addition, which is indicated by an arrow. The mitochondrial uncoupler CCCP (50 μM) was used as a control. Results are expressed as relative total ﬂuorescence [ratio of ﬂuorescence
difference (F − Fo), to basal value (Fo)] × 100 over time and are representative of 3 independent experiments in which at least 10 cells were analyzed in each case.
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identify necrotic cell death, was used in parallel. Unexpectedly as
shown in Fig. 1, 6 h of treatment with C2-ceramide induced both early
apoptosis and delayed necrosis. Whereas necrosis was only detected
by LDH release after 6 h treatment, early apoptotic markers, such as
cyt-c re-distribution were detected earlier (3 h). Ceramide-induced
cell deathwas apparently Ca+2-dependent (Fig. 2E) and cyt-c redistribu-
tion was delayed upon addition of either EGTA or Gd3+. Consequently,
we only observed decreases in ATP after 6 h of ceramide treatment,
correlating with the increased LDH release, which is in agreement with
the general perception that apoptosis requires ATPwhile necrosis occursin its absence. Moreover, in contrast to those models where primary
necrosis occurs, secondary necrosis usually follows apoptosis if the
removal of apoptotic bodies is delayed or absent, as is the case of cell
culturemodels [51]. In these cases, necrotic events, such as LDH release,
occur coincident with or after cyt-c release [52], observations that
strongly correlate with the results described in the present study.
4.2. Ceramide, second messengers and executors of cell death
It has been shown that ceramides increase cytoplasmic Ca2+ con-
centrations in different types of cells. Indeed, cytoplasmic Ca2+ levels
Fig. 6. Improved mitochondrial function prevents cardiomyocyte death induced by
C2-ceramide. Effects of methyl-pyruvate (5 mM) in cells treated with C2-ceramide (C2,
20 μM) 6 h on (A) PI Incorporation, n = 5; (B) mitochondrial potential, n = 5 and;
(C) intracellular levels of ATP, n = 7. *P b 0.05, ***P b 0.001 vs. Control (Co) and
#P b 0.05, ##P b 0.01 and ###P b 0.001 vs. C2 6 h.
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dition to ATP-dependent Ca2+ inﬂux, ceramide increases Ca2+ from a
thapsigargin-sensitive Ca2+ pool and triggers a subsequent capacitative
Ca2+ entry in Jurkat T cells [53]. In the aforementioned studies, increased
cytoplasmic Ca2+ concentrations were linked to the liberation of Ca2+
from intracellular stores and the activation of a store-operated Ca2+
channel [53]. Similarly, in our study ceramide increased cytoplasmic
Ca2+ was necessary for the subsequent cardiomyocyte death because
both, EGTA and Gd3+ decreased PI incorporation and also prevented
the deleterious effects of ceramide on ψmt and intracellular ATP levels
(Fig. 3C–D). Activation of calpains due to increased intracellular Ca2+
concentrations has been linked to cardiomyocyte death [54]. Our data
agree with these observations because two different calpain inhibitors
(leupeptin and E64D) and siRNAs for these proteases prevented the
ceramide-induced cardiomyocyte death. However, they did not exert
the same inhibitory effect on ψmt and the intracellular levels of ATP
(Fig. 4). These results suggest that calpain activation represents an
event that occurs downstream of mitochondrial dysfunction during
cardiomyocyte death. Interestingly, caspases seem not to be involved in
cardiomyocyte death induced by C2-ceramide (Fig. 4A). These results
are in agreement with studies in neuroblastoma cells where synthetic
ceramides induced a caspase-independent, necrosis-like morphology
[55]. Moreover, ceramides kill normal lymphocytes and lymphoid cell
lines in the absence of caspase activation, triggering a nonapoptoticmorphology in dying cells [47]. Thus, ceramide-induced cell death is
apparently not regulated by caspase activation, although the type of
death triggered by these lipids is strongly dependent on the cell type
and context.
4.3. Ceramide, mitochondrial morphology and function
Different studies have shown that ceramides alter the homeostasis
of several organelles, including particularly mitochondria [56].
According to this evidence, C2- and C16-ceramides form channels in
planar lipid bilayers allowing the release of cyt-c [56]. On the other
hand, C2-ceramide also decreases ψmt in isolated heart mitochondria
[57]. Our previous study established that C2-ceramide regulates mito-
chondrial dynamics through the stimulation of mitochondrial ﬁssion,
involved among other events in the activation of cardiomyocyte apo-
ptosis [14]. This ﬁssion process was accompanied by early translocation
of the ﬁssion protein Drp-1 to the mitochondria [14]. However, the
mechanisms that trigger this process remained unknown.
In the present study, we show that C2-ceramide not only induces
mitochondrial ﬁssion, but also decreases ψmt and the intracellular
levels of ATP (Fig. 5A–E). Also, histamine-induced mitochondrial
Ca+2 uptake in cardiomyocytes is reduced (Fig. 5F), suggesting that the
fragmented mitochondria observed in ceramide-treated cells display a
lower Ca2+ buffering capacity. Moreover, this may explain the increase
in cytosolic Ca2+ observed following C2-ceramide treatment and the sub-
sequent activation of calpains as effectors of cell death. These data agree
with previous reports establishing that a fragmented mitochondrial
network affects mitochondrial Ca2+ buffering capacity and the spatial
and temporal development of cytoplasmic Ca2+signals [41]. Increases
in cytosolic Ca2+ trigger the translocation of the protein Drp1 to the
mitochondria, thereby unleashing mitochondrial fragmentation [58].
In our graphical abstract we propose a model where C2-ceramide
induces an increase in cytosolic Ca2+, which triggers mitochondrial
network fragmentation and a decrease in the function of this organelle.
In this scenario, mitochondrial fragmentation reduces the mitochondrial
Ca+2 buffering capacity, increases cytosolic Ca2+ levels and activates
calpains.
Finally, one of the most interesting ﬁndings of this study was the
ability of MP to partially prevent the decrease in mitochondrial me-
tabolism and preclude cardiomyocyte death (Fig. 6). Constitutive
InsP3R-dependent Ca+2 release to mitochondria is an essential event
required for efﬁcient mitochondrial respiration and the maintenance of
normal cell bioenergetics [45,59]. This process seems to be altered in
cardiomyocytes treated with exogenous ceramides, given that histamine
stimulation results in reduced mitochondrial Ca+2 uptake following
ceramide treatment. Future work should clarify whether metabolic
rescue by MP prevents the reduction in mitochondrial Ca+2 buffering
capacity and also whether this may represent a beneﬁcial approach to
treat other pathological states where ceramides are implicated.
4.4. Concluding remarks
Our data provide novel evidence that cardiomyocyte mitochondria
are primary targets of cell-permeable ceramides. These sphingolipids
promote cytosolic Ca+2 inﬂux, mitochondrial fragmentation and
dysfunction, as well as cell death through apoptosis and necrosis.
Our results also show that mitochondrial dysfunction following
C2-ceramide-induced mitochondrial ψmt and ATP decrease is a
major driving force for cardiomyocyte apoptosis. Thus, metabolic
rescue observed upon addition of MP may represent an appropriate
strategy to avoid cardiomyocyte death in a broad range of cardiac
pathologies where ceramides and calpain activation may play a major
role, such as in ischemia-reperfusion [36,60] and doxorubicin treatment
[61,62].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2013.04.009.
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